NASDAQ:CRSP CRISPR Therapeutics Q4 2025 Earnings Results & Report $50.44 -1.91 (-3.65%) Closing price 10/8/2026 04:00 PM EasternExtended Trading$50.98 +0.54 (+1.06%) As of 05:41 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. CRISPR Therapeutics missed analyst expectations on both earnings and revenue in its Q4 2025 results, released February 13, 2026. The company reported EPS of -$1.37 versus the -$1.15 consensus estimate, while revenue of $0.86 million fell short of the $4.72 million estimate by $3.86 million. Revenue decreased 97.8% year over year. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateFebruary 13, 2026TimeBefore Market OpensConference Call DateFebruary 12, 2026Conference Call4:00 PM ET CRISPR Therapeutics EPS ResultsActual EPS-$1.37Consensus EPS -$1.15Beat/MissMissed by -$0.22One Year Ago EPS-$1.01EPS Beat Rate5 of last 8 quartersCRISPR Therapeutics Revenue ResultsActual Revenue$0.86 millionExpected Revenue$4.72 millionBeat/MissMissed by -$3.86 millionYoY Revenue Growth-97.80%Upcoming EarningsCRISPR Therapeutics' Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 3, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) CRISPR Therapeutics Q4 2025 Earnings FAQ Did CRISPR Therapeutics beat earnings estimates for Q4 2025? CRISPR Therapeutics (NASDAQ:CRSP) reported earnings of -$1.37 per share for Q4 2025, missing the consensus estimate of -$1.15. The report was announced on Friday, February 13, 2026. What was CRISPR Therapeutics' revenue for Q4 2025? CRISPR Therapeutics reported revenue of $0.86 million for Q4 2025, against a consensus estimate of $4.72 million. When is CRISPR Therapeutics' next earnings date? CRISPR Therapeutics' next earnings date is estimated for Monday, November 9, 2026. MarketBeat tracks confirmed and estimated earnings dates for CRISPR Therapeutics on the company's earnings history page. CRISPR Therapeutics Earnings HeadlinesCRISPR Therapeutics AG (NASDAQ:CRSP) Stock Now Rated "Moderate Buy" by Wall Street Analysts2 hours ago | americanbankingnews.comCRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026October 8 at 10:04 AM | finance.yahoo.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result. | Porter & Company (Ad)CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026October 8 at 8:30 AM | globenewswire.comIs Agilon Health (AGL) Stock Outpacing Its Medical Peers This Year?October 7 at 1:49 PM | finance.yahoo.comCRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You TradeOctober 6 at 10:36 PM | finance.yahoo.comSee More CRISPR Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CRISPR Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CRISPR Therapeutics and other key companies, straight to your email. Email Address About CRISPR TherapeuticsCRISPR Therapeutics (NASDAQ:CRSP) (NASDAQ: CRSP) is a biotechnology company focused on developing gene-editing medicines based on CRISPR/Cas9 technology. The company aims to treat serious diseases by precisely modifying genetic material in patients’ cells, with research programs spanning hematology, oncology, autoimmune diseases, and regenerative medicine. Its lead product, CASGEVY (exagamglogene autotemcel), is a CRISPR/Cas9-based cell therapy developed with Vertex Pharmaceuticals. CASGEVY is approved in multiple markets, including the United States, United Kingdom, and European Union, for certain patients with sickle cell disease and transfusion-dependent beta thalassemia. The therapy uses a patient’s own blood stem cells, which are edited outside the body and then reinfused. Founded in 2013, CRISPR Therapeutics conducts research and clinical development internationally, with operations and activities in North America and Europe. The company was co-founded by Emmanuelle Charpentier, Rodger Novak, and other scientists, and is led by Chief Executive Officer Samarth Kulkarni.View CRISPR Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Levi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueSkydance Just Became a Media Giant—With an $80 Billion Debt LoadConstellation Brands Beat Earnings, But Beer Demand Is Still a ProblemTesla's EV Delivery Beat Is In, So What Happens Now?BigBear.ai Is Heavily Shorted—and Its Fundamentals Are Starting to ChangePenguin Solutions Is Soaring as AI Memory Demand Explodes Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
